Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self-perceived muscle side effects

J Intern Med. 2022 Jun;291(6):891-893. doi: 10.1111/joim.13454. Epub 2022 Feb 1.

Elise Sverre^{1

2}, Kari Peersen^{2

3}, Oscar Kristiansen^{1

2}, Morten W Fagerland⁴, Joep Perk⁵, Einar Husebye¹, Nils Tore Vethe⁶, Toril Dammen⁷, John Munkhaugen^{1

2}

¹ Department of Medicine, Drammen Hospital, Drammen, Norway.
² Department of Behavioural Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
³ Department of Cardiology, Vestfold Hospital, Tønsberg, Norway.
⁴ Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.
⁵ Faculty of Health Sciences, Linnaeus University, Kalmar, Sweden.
⁶ Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
⁷ Division of Mental Health and Addiction, Oslo University Hospital, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

No abstract available

Keywords: coronary heart disease; lipid-lowering treatment; low-density lipoprotein cholesterol; statin-associated muscle symptoms; statins.

Publication types